Boston Scientific launches study of Watchman FLX device in non-valvular atrial fibrillation

• Boston Scientific (NYSE:BSX) initiates a new study, CHAMPION-AF, evaluating its WATCHMAN FLX Left Atrial Appendage Closure (LAAC) device in a broad population of patients with non-valvular atrial fibrillation, including those at low-to-moderate risk of bleeding from the use of anticoagulation therapies.
• The 3K-subject trial will compare the device to treatment with oral non-vitamin K antagonist anticoagulants as measured by the rates of cardiovascular death, stroke, systemic embolism and post-procedural major or clinically relevant non-major bleeding. Participants will be followed for five years.
• https://seekingalpha.com/news/3628242-boston-scientific-launches-study-of-watchman-flx-device-in-non-valvular-atrial-fibrillation